Wednesday Dec 4
Vertex Pharmaceuticals Incorporated - SWOT, Strategy and Corporate...
Vertex Pharmaceuticals Incorporated - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information.
Vertex: CF Drug Approval To Save The Company
Innovation is the passport to the future growth in the biotechnology industry. As long as the companies in this industry are able to come up with blockbuster drugs and get them approved by the U.S. Food and Drug Administration "FDA" to actively replace the loss of exclusivity of earlier patents, all is good to go.
Boston Capital Drug makers' risks, patients' hopes
Bonnie Astroff was just the kind of medical patient scientists at Vertex Pharmaceuticals Inc. had in mind for many years.
FLITE Awarded Record Grant to Help T/E District Students
The Foundation for Learning in Tredyffrin and Easttown has been awarded the biggest single grant in the organization's history.
BRIEF: Two biotechs get $100M-plus injections
Nov. 21 --Two Cambridge biotech companies added more than $100 million to their coffers yesterday, but for every different reasons.
Vertex Sells INCIVO Product Royalty Rights for $152 Million
"The monetization of INCIVO royalties provides cash to enhance our corporate financial position and continues to position us to support our investment in cystic fibrosis and to advance other key opportunities in our pipeline," said Ian Smith, Executive Vice President and Chief Financial Officer of Vertex.
Vertex: A Biotech Value Investment
The collapse of Vertex's hepatitis business has knocked the share price down about 30% from its recent high of $89.96 for a current enterprise value of $13 billion.
Vertex To Present at Upcoming Investor Conferences
Vertex Pharmaceuticals Incorporated announced that it will present at the Credit Suisse Healthcare Conference in Scottsdale, AZ on Tuesday, November 12 at 1:30 p.m. ET.